Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.39 |
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | HBB | P68871 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | JUN | P05412 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.37 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4203197 | 1.00 | NPC1 (0.39) | NPC1MAPTRAB9ASMN1; SMN2CYP1A2 | |
| SCHEMBL6047849 | 0.81 | NPC1 (0.42) | NPC1RAB9ASMN1; SMN2HPGDMEN1 | |
| SCHEMBL9647720 | 0.79 | KDM1A (0.34) | KDM1AHDAC6 | |
| SCHEMBL9647725 | 0.79 | KDM1A (0.34) | KDM1AHDAC6 | |
| SCHEMBL2010366 | 0.77 | KDM1A (0.33) | KDM1AHDAC6 | |
| SCHEMBL22333986 | 0.73 | MAPT (0.38) | NPC1MAPTRAB9ASMN1; SMN2CYP1A2 | |
| SCHEMBL107198 | 0.72 | MAPT (0.61) | NPC1MAPTRAB9ASMN1; SMN2CYP1A2 | |
| SCHEMBL138489 | 0.72 | MAPT (0.61) | NPC1MAPTRAB9ASMN1; SMN2CYP1A2 | |
| SCHEMBL4206183 | 0.71 | MAPT (0.50) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL4206179 | 0.71 | MAPT (0.50) | NPC1MAPTRAB9ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172340-A1 | Compositions and Methods for Selectively Activating Human Sirtuins | BIOMOL INTERNATIONAL L.P. (US) | 2012-07-05 | — | — | US | claimed |
| US-20060014705-A1 | Compositions and methods for selectively activating human sirtuins | BIOMOL INTERNATIONAL, INC. | 2006-01-19 | — | — | US | claimed |
| WO-2006004722-A2 | COMPOSITIONS AND METHODS FOR SELECTIVELY ACTIVATING HUMAN SIRTUINS | BIOMOL RESEARCH LABORATORIES, INC. (US) | 2006-01-12 | — | — | WO | claimed |
| US-10813934-B2 | Sirtuin modulators as inhibitors of cytomegalovirus | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2020-10-27 | — | — | US | disclosed |
| EP-2670404-B1 | SIRTUIN MODULATORS AS VIRUS PRODUCTION MODULATORS | UNIV PRINCETON (US) | 2018-08-29 | — | — | EP | disclosed |
| US-20160296523-A1 | Sirtuin Modulators as Inhibitors of Cytomegalovirus | THE TRUSTEES OF PRINCETON UNIVERSITY | 2016-10-13 | — | — | US | disclosed |
| US-20130338178-A1 | SIRTUIN MODULATORS AS INHIBITORS OF CYTOMEGALOVIRUS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2013-12-19 | — | — | US | disclosed |
| US-20120172340-A1 | Compositions and Methods for Selectively Activating Human Sirtuins | BIOMOL INTERNATIONAL L.P. (US) | 2012-07-05 | — | — | US | disclosed |
| US-20090012130-A1 | Strategies for Designing Drugs that Target the Sir2 Family of Enzymes | THE JOHNS HOPKINS UNIVERSITY (US) | 2009-01-08 | — | — | US | disclosed |
| US-20060014705-A1 | Compositions and methods for selectively activating human sirtuins | BIOMOL INTERNATIONAL, INC. | 2006-01-19 | — | — | US | disclosed |
| WO-2006004722-A2 | COMPOSITIONS AND METHODS FOR SELECTIVELY ACTIVATING HUMAN SIRTUINS | BIOMOL RESEARCH LABORATORIES, INC. (US) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10813934-B2 | Sirtuin modulators as inhibitors of cytomegalovirus | SIRT1, SIRT2, SIRT7 | NPC1 2730/4885MAPT 2621/4885RAB9A 3558/4885 |
| US-20160296523-A1 | Sirtuin Modulators as Inhibitors of Cytomegalovirus | SIRT1, SIRT2, SIRT7 | NPC1 2730/4885MAPT 2621/4885RAB9A 3558/4885 |
| US-20120172340-A1 | Compositions and Methods for Selectively Activating Human Sirtuins | SIRT1, SIRT7, SIRT5 | NPC1 1838/4885MAPT 3039/4885RAB9A 3172/4885 |
| US-20130338178-A1 | SIRTUIN MODULATORS AS INHIBITORS OF CYTOMEGALOVIRUS | SIRT1, SIRT2, SIRT7 | NPC1 2730/4885MAPT 2621/4885RAB9A 3558/4885 |
| US-20060014705-A1 | Compositions and methods for selectively activating human sirtuins | SIRT1, SIRT7, SIRT5 | NPC1 1838/4885MAPT 3039/4885RAB9A 3172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.